玫瑰痤疮面部潮红与红斑新认识

doi:10.35541/cjd.20190920

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (4): 360-363.doi: 10.35541/cjd.20190920

玫瑰痤疮面部潮红与红斑新认识

李健宋志强

陆军军医大学西南医院皮肤科，重庆 400038

收稿日期:2019-09-23 修回日期:2020-06-04 发布日期:2021-03-31
通讯作者: 宋志强 E-mail:zhiqiang.song@hotmail.com
基金资助:
国家自然科学基金（81703154）；陆军军医大学西南医院青年人才培养计划项目（SWH2018QNLC-03）

New insights into facial flushing and erythema in rosacea

Li Jian, Song Zhiqiang

Dermatology Department, Southwest Hospital of Army Medical University, Chongqing 400038, China

Received:2019-09-23 Revised:2020-06-04 Published:2021-03-31
Contact: Song Zhiqiang E-mail:zhiqiang.song@hotmail.com
Supported by:
National Natural Science Foundation of China （81703154）; Youth Talent Training Program of Southwest Hospital of Army Medical University （SWH2018QNLC-03）

摘要/Abstract

摘要： 【摘要】持续型面中部红斑与潮红是玫瑰痤疮最常见的临床表现，但对其病理机制了解甚少，并缺乏高证据等级临床研究支持。本文结合国内外研究进展及临床经验，强调将面部潮红与红斑作为独立的临床表型进行研究探讨的必要性，认为精神压力、焦虑和/或抑郁可能是其发病的使动环节。由精神因素出发，探索玫瑰痤疮面部潮红及红斑相关神经炎症与皮肤免疫及血管的关系具有潜在的临床意义。

关键词: 红斑痤疮, 潮红, 红斑, 焦虑, 精神压力, 神经炎症

Abstract: 【Abstract】 Persistent centrofacial erythema with transient flushing is the most common clinical manifestation of rosacea. However, its pathological mechanisms are poorly understood, and there is a lack of high-level evidence from clinical studies. Based on research progress and clinical experience in China and other countries, the authors emphasize the necessity that facial flushing with erythema should be investigated as an independent clinical phenotype during the study. It is believed that mental stress, anxiety and/or depression may be driving factors in the pathogenesis of facial flushing with erythema. Based on mental factors, it is of potential clinical significance to investigate the relationship of neuroinflammation involved in facial flushing and erythema with skin immunity and blood vessels in rosacea.

Key words: Rosacea, Flushing, Erythema, Anxiety, Mental stress, Neuroinflammation

李健宋志强. 玫瑰痤疮面部潮红与红斑新认识[J]. 中华皮肤科杂志, 2021,54(4):360-363. doi:10.35541/cjd.20190920

Li Jian, Song Zhiqiang. New insights into facial flushing and erythema in rosacea[J]. Chinese Journal of Dermatology, 2021, 54(4): 360-363.doi:10.35541/cjd.20190920

参考文献 30

［1］	Rueda LJ, Motta A, Pabón JG, et al. Epidemiology of rosacea in Colombia［J］. Int J Dermatol, 2017,56（5）:510⁃513. doi: 10. 1111/ijd.13491.
［2］	Johnston SA, Krasuska M, Millings A, et al. Experiences of rosacea and its treatment: an interpretative phenomenological analysis［J］. Br J Dermatol, 2018,178（1）:154⁃160. doi: 10.1111/bjd.15780.
［3］	Tan J, Steinhoff M, Berg M, et al. Shortcomings in rosacea diagnosis and classification［J］. Br J Dermatol, 2017,176（1）:197⁃199. doi: 10.1111/bjd.14819.
［4］	Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus （ROSCO） panel［J］. Br J Dermatol, 2017,176（2）:431⁃438. doi: 10.1111/bjd.15122.
［5］	Forero Molina MA, Garcia E, Gonzalez⁃Devia D, et al. A 17⁃year⁃old male with a small bowel neuroendocrine tumor: flushing differential diagnosis［J］. World Allergy Organ J, 2017,10（1）:30. doi: 10.1186/s40413⁃017⁃0161⁃4.
［6］	Sadeghian A, Rouhana H, Oswald⁃Stumpf B, et al. Etiologies and management of cutaneous flushing: nonmalignant causes［J］. J Am Acad Dermatol, 2017,77（3）:391⁃402. doi: 10.1016/j.jaad.2016.12.031.
［7］	Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis［J］. J Clin Oncol, 2009,27（17）:2831⁃2837. doi: 10. 1200/JCO.2008.19.6253.
［8］	Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update［J］. J Am Acad Dermatol, 2018,78（4）:786⁃792.e8. doi: 10.1016/j.jaad.2017.09.016.
［9］	Egeberg A, Ashina M, Gaist D, et al. Prevalence and risk of migraine in patients with rosacea: a population⁃based cohort study［J］. J Am Acad Dermatol, 2017,76（3）:454⁃458. doi: 10. 1016/j.jaad.2016.08.055.
［10］	Egeberg A, Hansen PR, Gislason GH, et al. Patients with rosacea have increased risk of depression and anxiety disorders: a danish nationwide cohort study［J］. Dermatology, 2016,232（2）:208⁃213. doi: 10.1159/000444082.
［11］	Scharschmidt TC, Yost JM, Truong SV, et al. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment［J］. Arch Dermatol, 2011,147（1）:123⁃126. doi: 10.1001/archdermatol.2010.413.
［12］	Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus （ROSCO） panel［J］. Br J Dermatol, 2017,176（2）:465⁃471. doi: 10.1111/bjd.15173.
［13］	Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1775⁃1791. doi: 10.1111/jdv.14349.
［14］	Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase Ⅲ clinical trials evaluating anti⁃inflammatory dose doxycycline （40⁃mg doxycycline, USP capsules） administered once daily for treatment of rosacea［J］. J Am Acad Dermatol, 2007,56（5）:791⁃802. doi: 10.1016/j.jaad.2006.11.021.
［15］	Park JM, Mun JH, Song M, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea［J］. J Dermatol, 2015,42（1）:64⁃69. doi: 10.1111/1346⁃8138.12687.
［16］	van der Linden M, van Ratingen AR, van Rappard DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single⁃blinded, noninferiority trial, comparing efficacy and safety［J］. Br J Dermatol, 2017,176（6）:1465⁃1474. doi: 10.1111/bjd.15155.
［17］	Two AM. Minocycline as an alternative to doxycycline in the treatment of rosacea［J］. Br J Dermatol, 2017,176（6）:1426. doi: 10.1111/bjd.15514.
［18］	Uslu M, Şavk E, Karaman G, et al. Rosacea treatment with intermediate⁃dose isotretinoin: follow⁃up with erythema and sebum measurements［J］. Acta Derm Venereol, 2012,92（1）:73⁃77. doi: 10.2340/00015555⁃1204.
［19］	van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments［J］. Br J Dermatol, 2019,181（1）:65⁃79. doi: 10.1111/bjd.17590.
［20］	Asai Y, Tan J, Baibergenova A, et al. Canadian clinical practice guidelines for rosacea［J］. J Cutan Med Surg, 2016,20（5）:432⁃445. doi: 10.1177/1203475416650427.
［21］	Two AM, Wu W, Gallo RL, et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors［J］. J Am Acad Dermatol, 2015,72（5）:749⁃760. doi: 10.1016/j.jaad. 2014.08.028.
［22］	Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation［J］. J Investig Dermatol Symp Proc, 2011,15（1）:33⁃39. doi: 10.1038/jidsymp.2011.8.
［23］	Gilman SE, Trinh NH, Smoller JW, et al. Psychosocial stressors and the prognosis of major depression: a test of Axis IV［J］. Psychol Med, 2013,43（2）:303⁃316. doi: 10.1017/S0033291712 001080.
［24］	Weber MD, Godbout JP, Sheridan JF. Repeated social defeat, neuroinflammation, and behavior: monocytes carry the signal［J］. Neuropsychopharmacology, 2017,42（1）:46⁃61. doi: 10.1038/ npp.2016.102.
［25］	Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases（review）［J］. Mol Med Rep, 2016,13（4）:3391⁃3396. doi: 10.3892/mmr.2016.4948.
［26］	Vidal Yucha SE, Tamamoto KA, Kaplan DL. The importance of the neuro⁃immuno⁃cutaneous system on human skin equivalent design［J］. Cell Prolif, 2019,52（6）:e12677. doi: 10.1111/cpr. 12677.
［27］	Hinwood M, Tynan RJ, Charnley JL, et al. Chronic stress induced remodeling of the prefrontal cortex: structural re⁃organization of microglia and the inhibitory effect of minocycline［J］. Cereb Cortex, 2013,23（8）:1784⁃1797. doi: 10.1093/cercor/bhs151.
［28］	Pietschke K, Schaller M. Long⁃term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol［J］. J Dermatolog Treat, 2018,29（3）:310⁃313. doi: 10.1080/09546634.2017.1360991.
［29］	Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β⁃adrenergic blocker［J］. J Am Acad Dermatol, 2012,67（3）:491⁃493. doi: 10.1016/j.jaad.2012.04.017.
［30］	Weihe E, Schütz B, Hartschuh W, et al. Coexpression of cholinergic and noradrenergic phenotypes in human and nonhuman autonomic nervous system［J］. J Comp Neurol, 2005,492（3）:370⁃379. doi: 10.1002/cne.20745.

[1]	王小燕, 张嘉文, 刘韵祎, 刘乙萱, 姜沛彧, 李敏, 陶梦, 许阳. 玫瑰痤疮的皮肤影像学和无创检测技术相关进展[J]. 中华皮肤科杂志, 2022, 0(1): 20200939-e20200939.
[2]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[3]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[4]	杨长志张晓萍杨子良周乃慧朱丽萍邵凯朱婷婷余秀琴. 成人皮肌炎患者抗核抗体与临床特征及肿瘤风险的关系[J]. 中华皮肤科杂志, 2021, 54(6): 480-484.
[5]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.
[6]	中华医学会皮肤性病学分会玫瑰痤疮研究中心中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）[J]. 中华皮肤科杂志, 2021, 54(4): 279-288.
[7]	邓青刘芳芬施为谢红付李吉黄莹雪. 长沙地区玫瑰痤疮患者的支付意愿调查及影响因素分析[J]. 中华皮肤科杂志, 2021, 54(4): 352-355.
[8]	张二佳林彤. 两种强脉冲光治疗玫瑰痤疮的疗效观察[J]. 中华皮肤科杂志, 2021, 54(3): 207-211.
[9]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2021, 54(2): 116-121.
[10]	罗帅寒天龙海张桂英陆前进. 2019年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(2): 183-186.
[11]	李玥玥骆丹. 皮肤微生物群在玫瑰痤疮发病中的作用及机制研究进展[J]. 中华皮肤科杂志, 2021, 54(12): 1122-1125.
[12]	宋晓婷, 刘擘, 陈玉迪, 赵作涛. 玫瑰痤疮的病理生理发病机制研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20200178-e20200178.
[13]	刘乙萱, 姜沛彧, 刘韵祎, 张嘉文, 陶梦, 李敏, 许阳. 玫瑰痤疮神经源性炎症及肉毒毒素治疗相关机制的研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20200266-e20200266.
[14]	万立, 陈金波, 姜倩, 陈红英, 胡彬, 陈柳青. 反射式共聚焦显微镜在界面皮炎中的应用研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20210269-e20210269.
[15]	李容, 张家安, 陈崑. 玫瑰痤疮光电疗法研究进展[J]. 中华皮肤科杂志, 2021, 0(1): 20201002-e20201002.

玫瑰痤疮面部潮红与红斑新认识

New insights into facial flushing and erythema in rosacea

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

Metrics

本文评价

推荐阅读 10